Inclusion Criteria:

          -  Locally advanced or metastatic and/or unresectable Hepatocellular Carcinoma (HCC)

          -  No prior systemic therapy for HCC. Previous use of herbal therapies/traditional
             Chinese medicines with anti-cancer activity included in the label is allowed, provided
             that these medications are discontinued prior to randomization.

          -  At least one measurable untreated lesion

          -  ECOG Performance Status of 0 or 1

          -  Adequate hematologic and end-organ function

          -  For women of childbearing potential: agreement to remain abstinent

          -  For men: agreement to remain abstinent

          -  Child-Pugh class A

        Exclusion Criteria:

          -  History of leptomeningeal disease

          -  Active or history of autoimmune disease or immune deficiency

          -  History of idiopathic pulmonary fibrosis, organizing pneumonia, drug-induced
             pneumonitis, or idiopathic pneumonitis, or evidence of active pneumonitis on screening
             chest computed tomography scan

          -  Known active tuberculosis

          -  History of malignancy other than HCC within 5 years prior to screening, with the
             exception of malignancies with a negligible risk of metastasis or death

          -  Pregnancy or breastfeeding, or intention of becoming pregnant during study treatment
             or within at least 5 months after the last dose of atezolizumab, 6 months after the
             last dose of bevacizumab, or 1 month after the last dose of sorafenib

          -  Known fibrolamellar HCC, sarcomatoid HCC, or mixed cholangiocarcinoma and HCC

          -  Untreated or incompletely treated esophageal and/or gastric varices with bleeding or
             high-risk for bleeding

          -  A prior bleeding event due to esophageal and/or gastric varices within 6 months prior
             to initiation of study treatment.

          -  Moderate or severe ascites

          -  History of hepatic encephalopathy

          -  Co-infection of HBV and HCV

          -  Symptomatic, untreated, or actively progressing central nervous system (CNS)
             metastases

          -  Uncontrolled tumor-related pain

          -  Uncontrolled pleural effusion, pericardial effusion, or ascites requiring recurrent
             drainage procedures

          -  Uncontrolled or symptomatic hypercalcemia

          -  Treatment with systemic immunostimulatory agents

          -  Inadequately controlled arterial hypertension

          -  Prior history of hypertensive crisis or hypertensive encephalopathy

          -  Evidence of bleeding diathesis or significant coagulopathy

          -  History of intestinal obstruction and/or clinical signs or symptoms of GI obstruction
             including sub-occlusive disease related to the underlying disease or requirement for
             routine parenteral hydration

          -  Serious, non-healing or dehiscing wound, active ulcer, or untreated bone fracture

          -  Metastatic disease that involves major airways or blood vessels, or centrally located
             mediastinal tumor masses

          -  Local therapy to liver within 28 days prior to initiation of study treatment or
             non-recovery from side effects of any such procedure

          -  Chronic daily treatment with a non-steroidal anti-inflammatory drug (NSAID)